IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that management is scheduled to participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference. Presentation details:Date: April 14, 2021Time: 10:15am EDT The presentation will be accessible via a live webcast at https://wsw.com/webc...

Even if it's not a huge purchase, we think it was good to see that Ronald Andrews, the CEO, President & Director of...

DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection Scheduled to present data at 2021 American Association for Cancer Research (AACR) Annual Meeting that supports DetermaIO’s potential pan-cancer applicability Strengthened balance sheet to support ramping commercialization of Oncocyte’s broadening product portfolio Conference call scheduled for 4:30 P.M. EDT IRVINE, Cal...

NEW YORK, NY / ACCESSWIRE / March 16, 2021 / OncoCyte Corp. (AMEX:OCX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 16, 2021 at 4:30 PM Eastern Time.

Novel immuno-oncology algorithm may offer independent and incremental predictive value over current standard biomarkers in the clinic Data suggest that measuring the tumor microenvironment (TME) as a whole may help optimize immunotherapy use in the clinical settingAuthors concluded that the immuno-oncology algorithm is capable of analyzing data from multiple platforms that have a wide global installed base, including PCR and NGS, and from gene expression data already available from pharma clinic...